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Background: Osteoporosis is a major health issue worldwide. Osteoporosis is 
characterized by the progressive decreasing in bone mass, microarchitecture decline 
of bone tissue, bone fragility and strength, which leads to an increase in risk of 
fracture. About a quarter of Norwegian women over 50 years of age were estimated to 
have the disease in 2010 and Norway has one of the highest reported incidence of hip 
fractures in the world with over 9000 hip fractures per year. There are numerous 
effective anti-osteoporosis drugs (AOD) for the prevention and treatment of 
osteoporosis and fracture. Despite of this, a number of studies have shown that 
patients are undertreated with AOD after fractures. 
The aim of the thesis is to describe the pattern of anti-osteoporosis drug use in a 
general population among persons with osteoporosis defined by self-report or by bone 
mineral density measurements, with or without fracture. 
Material and Method: A cross-sectional study was conducted based on data 
from the sixth survey of the Tromsø study (Tromsø 6), which took place in 2007-
2008. The data included information from questionnaires and physical examinations 
of the total study population (n=12981) and additionally bone mineral density 
measurements from a subpopulation (n=3663).   
Results: The prevalence of anti-osteoporosis drug use among participants reporting 
osteoporosis in the total population was less than 50%. In the subpopulation the 
prevalence of anti-osteoporosis drug use among participants that are eligible for 
treatment with anti-osteoporosis drug was under 20%, and only 20% of these 
participants were aware that they had osteoporosis. Bisphosphonates was the most 
frequently used anti-osteoporosis drug type. Prevalence of bisphosphonates use 
among those in need of treatment within the subpopulation was 11%. 
Conclusion: This study revealed that the prevalence of anti-osteoporosis drug use 
among persons eligible for anti-osteoporosis drug treatment is very low, although 
higher among persons reporting that they had both osteoporosis and fracture. 





AOD   Anti-osteoporosis drugs 
BMD   Bone mineral density 
WHO   World Health Organization 
DXA   Dual X-ray absorptiometry 
HRT   Hormone replacement therapy 
SERMs    Selective estrogen receptor modulators 
PTH   Parathyroid hormone 
SPSS   Statistical Package for the Social sciences 
+FX   With fracture 
-FX   Without fracture 
BMI   Body mass index 
RANKL  Receptor activator of nuclear factor kappa-B ligand 






Osteoporosis and osteoporotic fracture is a major health issue worldwide, with an 
estimated 200 million people having osteoporosis (1). About one out of every two 
women and one out of five men 50 years and older, will have an osteoporosis-related 
fracture in their lifetime. Osteoporotic fractures are associated with increased 
mortality, morbidity, disability and reduced quality of life (2). In Norway, hip fracture 
accounted for 5% of all deaths among women and men aged 50 years and older, 
between the years 1999-2008 (3).  
In the year 2000, there was a worldwide estimate of 9 million new osteoporotic 
fractures of which 1.6 million was hip and 1.7 million was forearm fractures (4). Two 
million fractures are attributed to osteoporosis annually in the US with a nearly cost 
of $17 billion in 2005 and the cost expected to rise to $25.3 billion by the year 2025 
(5). 
In the year 2010, approximately 22 million women and 5.5 million men were 
estimated to have osteoporosis in the European Union (6). Three and a half million 
new osteoporotic fractures were sustained of which 610 000 and 560 000 comprised 
of hip and forearm fracture, with a direct cost estimated at £39 billion (6). 
The highest incidence of osteoporotic fracture is reported in Scandinavia, and Norway 
has one of the highest reported incidence of fractures in the world with an estimate of 
about 9000 hip fractures and 15 000 forearm fracture per year (7). About a quarter of 
Norwegian women over 50 years of age is estimated to have osteoporosis (7). A 
recent study reported a decline in hip fracture incidence in Norway, by 20.4% in 
women and 10.8% in men (8). However the growing number of older persons in the 
Norwegian population might cause an increase in the future prevalence of 
osteoporosis and osteoporotic fracture (8, 9). 
1.1 What is osteoporosis? 
In the body, old bone is constantly being removed by bone-resorbing cells known as 
osteoclasts and being replaced by new bone by bone-formation cells called osteoblasts 
(10). Bone loss occurs when there is an imbalance in this process leading to more 
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bone removal than replacement. Figure 1 shows the changes with bone as a result of 
bone loss.  
Osteoporosis is a disease characterized by the progressive reduction of bone mass, 
microarchitecture decline of bone tissue, bone fragility and strength, which leads to an 
increase in the risk of fracture (11, 12). The World Health Organization defines 
osteoporosis as “a bone mineral density (BMD) that lies 2.5 standard deviations or 
more below the average value for young healthy women (a T-score of <-2.5 SD)” 
(13). Osteoporosis does not show any symptoms or pain and is often not diagnosed or 
treated until a fracture occurs (14). It is therefore regarded more as a risk factor of 
bone fracture than a disease. Osteoporotic fractures usually occurs in hip, spine or 
forearms, with hip fractures being the most serious outcome of osteoporosis(15). Hip 
fracture often occurs late in life and is often associated with acute and chronic pain, 
disability, high social cost, depression and excess morbidity and mortality (2, 16). It 
also increases the risk for future fractures by two and a half folds. Wrist fractures are 
less disabling, but are often precursors of more serious fractures. Therefore the 
identification and treatment of persons at risk of fracture is important. Persons at high 
risk for fracture are those with previous fracture, low bone mass and established 
osteoporosis (12).  
 





1.2 Risk factors 
Osteoporosis is known to be commonly caused by aging (10), with the loss of bone 
mass in both genders being a result of advancing age and in postmenopausal women 
being associated with estrogen reduction, particularly with early menopause (17, 18). 
Diseases like rheumatoid arthritis and the long-term use of drugs like corticosteroids 
have been shown to also induce what is known as secondary osteoporosis (19). 
1.2.1 Age and gender 
Osteoporosis affects women more than men, and women have almost twice the risk 
for hip fracture compared with men (20). This is mainly because of accelerated bone 
loss in women during the menopausal transition. The decline of estrogen 
concentration is associated with progressive bone loss with an estimated lifetime risk 
for fracture of about 50% for women above 50 years. Since men do not undergo a 
menopausal period, bone loss is therefore sustained later in life (17, 20).  
Although osteoporosis mainly affects women, it is also a threat to men. About 20% of 
men over the age of 60 years will experience an osteoporotic fracture in their lifetime 
(21). Men over the age of 50 years lose one-half as much bone and have three-fold 
increase in fracture risk compared to postmenopausal women (22). 
The risk of osteoporosis and fracture increases with age, particularly 65 years of age 
(23), mainly because of an imbalance between bone-resorbing osteoclasts and bone-
forming osteoblast. The likeliness of falling is also higher at old age (23, 24). Both 
men and women with previous fractures, especially hip or spine fracture, have twice 
the risk of suffering a fracture compared to people of the same age and sex without 
previous fracture. People with multiple fractures have an eight-fold increase in 
fracture risk (25). 
1.2.2 Secondary causes  
Psychotropic medications among other drugs have been shown to increase the 
incidence of falling among older adult by 47%, which also increases the risk of 
sustaining a fracture (26). Conditions such as diabetes mellitus, vitamin D deficiency, 
rheumatoid arthritis and a variety of other conditions can also increase the risk for 
fracture and osteoporosis (14). Low body weight, having a small body frame, family 
history of osteoporosis, smoking, high alcohol intake, and medications like 
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glucocorticoids, have been shown to increase the risk for osteoporosis (27). 
Glucocorticoid-induced osteoporosis is the most common cause of secondary 
osteoporosis. It is estimated that 30% of all patients on chronic glucocorticoid therapy 
will develop osteoporosis, and up to 50% of the patients will experience a fracture 
(28).  
1.3 Diagnosis 
Bone mineral density (BMD) measurement is used in the diagnosis of osteoporosis 
(14). There are a variety of methods to measure bone mineral density including 
quantitative computed tomography (QCT), quantitative ultrasound (QUS), and X-ray 
absorptiometry. X-ray based absorptiometry methods are the most used, especially 
dual energy X-ray absorptiometry (DXA) because of its ability to be used to assess 
bone mineral of the entire skeleton as well as specific sites. Calcium content in bone 
tissue is also very sensitive to X-ray absorption, however traditional X-rays cannot 
measure bone density, but they can identify spine fractures. Measurements are taken 
at the spine, hip and or forearm. BMD measurement is however, not the only 
diagnostic criteria of osteoporosis. A number of clinical risk factors including parental 
history of hip fracture, prior fragility fracture, age, use of systemic corticosteroids, 
excess alcohol intake, tobacco smoking and having rheumatoid arthritis are also used 
(14).  
 
1.3.1 Bone mineral density classification 
BMD is often classified by T- or Z- score. T-score is the number of standard 
deviations (SDs) by which BMD of an individual differs from the mean value of a 
reference population (figure 2). The T-score diagnosis of normal, low bone mass and 
osteoporosis is based on the WHO diagnostic classification (table 1) (13). This only 
applies for the diagnostic use in postmenopausal Caucasian women and men aged 50 
years or more (29).  
The International society for Clinical Densitometry recommends that Z-score instead 
of a T-score should be used in bone mineral density reporting of women before 
menopause and men younger than 50 years of age (30). Z-score is a comparison of the 
patient’s BMD to an age-, sex-, and ethnicity-matched reference population. Z-scores 
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of −2.0 or lower defined as either “low bone mineral density for chronological age” or 
“below the expected range for age” and those above −2.0 being “within the expected 
range for age”(30). 
 
 




Table 1 WHO diagnostic T-score classification 
Category T-score 
Normal -1.0 SD or higher 
Osteopenia (low bone mass) -1.0 ≥ -2.5 SD 




In 2005 the Norwegian Directorate of Health released the Norwegian guidelines for 
prevention and treatment of osteoporosis and osteoporotic fractures (31). The 
guidelines recommended preventive measures including adequate calcium and 
vitamin D inntake, either through food or supplements, lifestyle changes (e.g. 
exercising, weight reduction, tobacco cessation and moderate alcohol intake), 
prevention of falls and if possible avoidance of glucocorticoid drugs for 
postmenopausal women and men age 50 and older (31). Persons that are 
recommended anti-osteoporosis drug treatment in addition to these preventive 
measures are postmenupausal women and men age 50 and older with a spine or hip 
fracture, thoses with a bone mineral density T-score ≤ -2.5 standard deviation below 
the mean value for a reference population (with or without fracture) and 
postmenupausal women and men age 50 and older with a previous fracture and a bone 
mineral density T-score ranging from -1.6 to -2.5 (31).  
1.4.1 Pharmacological treatment 
Pharmacological treatment of osteoporosis can be divided into two groups, 
antiresorptive drugs, i.e. those that slow down bone resorption like bisphosphonates, 
raloxifene and denosumab, and anabolic drugs that stimulate bone formation, like 
parathyroid hormone (PTH). 
1.4.2 Bisphosphonates 
Bisphosphonates are the main prophylactic treatment against osteoporosis and 
fracture. They are anti-resorptive agents with high affinity for hydroxyapatite, the 
mineral component of the bone, and are able to achieve high local concentration 
within the skeleton (32). This leads to effective limitation of osteoclast-mediated bone 
resorption, increasing BMD and reduction in fracture risk. Bisphosphonates have 
been shown to reduce fracture risk about 30%-50% in persons with existing vertebral 
fracture and also those with low bone mineral density (T-score < -2.5) (33). 
Bisphosphonates have also been shown to reduce the risk of fracture (34), stop bone 
loss and improve bone mineral density in men and in both pre- and postmenopausal 
women (35, 36).  
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Bisphosphonates are given orally or intravenously and are most widely used because 
of their ability to be used in the treatment of all osteoporosis types, including 
osteoporosis in men, postmenopausal women and glucocorticoid-induced 
osteoporosis. Bisphosphonates have <1% bioavailability when taken orally and it is 
therefore important to take it correctly. To prevent gastroesophageal side effects and 
ensure optimum absorption, patients must take the drug with water before meals and 
in an upright position (37). Randomized controlled trails (RCT) have shown that 
bisphosphonates have a relatively low risk profile when taken correctly (38). Despite 
their low risk profile, adverse effects like gastrointestinal upset, muscle pain, 
dyspepsia, esophagitis and obstipation have been reported in association with oral 
bisphosphonates (39). Osteonecrosis of the jaw, which is a very rare condition 
occurring with one out of 100 000 patients, have been reported in association with 
long-term usage (39, 40). Available bisphosphonates in Norway includes alendronate, 
risedronate, and ibandronate in oral formulations and zolendronate being used 
intravenously. Sales of bisphosphonates were at 78 million NOK in 2008 with 
alendronate constituting 95% of the sales (figure 3). Nearly 57 000 people had at least 
one bisphosphonate retrieved from pharmacies during 2007-2008 (figure 4), of which 
90% were women (41). Bisphosphonates are the first in line anti-osteoporosis drug 
recommended by the Norwegian health authorities, which is in accordance with 
international guidelines (31, 42). 
 
Figure 3 Sales of bisphosphonates (M05) in Norway from 1992 to 2014. Sales are given in 




























































































































Figure 4 Dispensed bisphosphonates in Norwegian pharmacies from 2004-2014. Only the most dispensed bisphosphonates are presented. Source: The 








































1.4.3 Hormone replacement therapy (HRT) 
Estrogen level is the most important factor for bone loss in postmenopausal women 
(43). Estrogen inhibits bone loss by binding to cellular receptors and suppressing 
osteoclast activity. Hormone replacement therapy has been shown to have good effect 
on osteoporosis as well as postmenopausal symptoms like hot flashes. Results from 
the Women’s Health Initiative study state an increase in bone mineral density and also 
reduction in risk for fracture among postmenopausal women on hormone estrogen 
(44). It is, however, no longer recommended as the first choice in the treatment and 
prevention of osteoporosis among postmenopausal women due to increased risk of 
breast cancer and cardiovascular and venous thromboembolic events. Hormone 
replacement therapy may be considered appropriate as treatment of osteoporosis for 
women already on estrogens for the treatment of climacteric syndrome (45).  
1.4.4 Denosumab 
Denosumab is a fully human monoclonal antibody that binds specifically to Receptor 
activator of nuclear factor kappa-B ligand (RANKL). RANKL is a regulatory 
molecule required for the formation and activation of osteoclast. Inhibition of 
RANKL results in a decrease in bone resorption due to the reduced formation of 
osteoclast. Denosumab given subcutaneously every six months for 36 months to 
postmenopausal women with osteoporosis was associated with an increase in bone 
mineral density and reduced risk of vertebral, hip and non-vertebral fracture (46).  
1.4.5 Selective estrogen receptor modulators (SERMs) 
SERMs as their name implies are drugs that act on estrogen receptors. Unlike other 
pure estrogen receptor agonist and antagonist, SERMs have the ability to selectively 
stimulate or inhibit estrogen-like action in various tissues (47). SERMs stimulate 
estrogenic action in bone, acting like estrogen to decrease bone resorption and 
improve bone mineral density, which in turn lead to the decreasing in risk of 
fracture. Raloxifene is the only SERM approved for the treatment and prevention of 
osteoporosis in postmenopausal women. Studies have shown significant increase in 
bone mineral density and risk reduction for vertebral facture in postmenopausal 
women with osteoporosis when treated with raloxifene (48, 49). However, raloxifene 
have some of the similar adverse effects as estrogen e.g. increases risk for thrombosis. 
It can also cause leg cramps and increase hot flashes. 
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1.4.6 Parathyroid hormone (PTH) 
Parathyroid hormone is the only anabolic agent available for the treatment of 
osteoporosis. Unlike the other anti-osteoporosis drug types that reduce bone 
resorption, PTH works by stimulating the formation of bone (50). A randomized 
controlled trial involving over 1600 postmenopausal women with established 
osteoporosis showed a decrease in the risk of vertebral and non-vertebral fracture by 
65% during 18 months of treatment with daily subcutaneous injection of PTH (51). 
Teriparatide is approved for the treatment of osteoporosis in both women and men 
with increase risk of fracture. A daily dose of 20 ug is recommend for a maximum 
treatment time of 24 months. Besides its effectiveness, treatment with PTH is 
expensive and it is also not directly reimbursed in Norway. The drug is therefore only 




1.5 The situation today 
Despite the burden on persons affected and the society, and the availability of cost 
effective drugs, both national and international studies have suggested that 
osteoporosis is undertreated (25, 52, 53). However, these studies were registry linkage 
studies and did not include diagnostic information or information on the personal 
level regarding self-perceived health and reports of adverse effects. It is therefore 
interesting to investigate the degree of anti-osteoporosis drug use among persons with 
osteoporosis and/or osteoporotic fractures in a population based health study with 




The main aim of the study is to describe the pattern of anti-osteoporosis drug use in a 
general population among persons with osteoporosis, with or without fracture based 
on questionnaire data and measurement of bone mineral density by dual energy X-ray 
absorptiometry.  
 
Other specific aims are to figure out whether:  
- Prevalence of anti-osteoporosis drug use varies across different diagnosis 
categories of osteoporosis. 
- Users of anti-osteoporosis drugs (i.e. bisphosphonates) have poorer health or 
experience more adverse effects (gastrointestinal symptoms or muscle/joint 








3 Material and Method 
3.1 The Tromsø study 
The Tromsø Study is a population-based, prospective study of various health issues, 
symptoms and chronic diseases (54). It was initiated in 1974 as a combined 
population health survey and a research study of cardiovascular diseases. The Tromsø 
Study has gradually expanded to include several chronic diseases and conditions like 
diabetes mellitus, atrial fibrillation, venous thromboembolism, osteoporosis and 
fracture. Six surveys have been carried out 6-7 years apart, referred to as Tromsø 1-6, 
and a seventh wave of the study is carried out now in 2015-2016. All surveys include 
questionnaire data, sampling of biological specimens, measurements and clinical 
examinations. Residents of the municipality of Tromsø are invited to take part in the 
survey by a personal invitation enclosed with a questionnaire by mail. The invitation 
includes information about the survey and the examinations. Tromsø 4-7 includes a 
second examination visit 2-4 weeks later with eligible participants being already 
identified before their first visit. The questionnaires include questions about disease 
and symptoms, use of medication, socio-economic status and life style (54). An 
attachment of the questionnaire used in the sixth survey of the Tromsø Study is at the 
appendix of this master thesis. Data from the six surveys are currently involved in 
over 100 different research projects (55, 56). 
3.2 Study population and design 
This is a cross-sectional study based on data from the sixth survey of the Tromsø 
Study (Tromsø 6), which took place in 2007-2008. Invited to participate in a two-part 
examination were all participants from the second visit of the fourth survey of the 
Tromsø Study who were still residing in Tromsø by September 2007. Additionally, all 
inhabitants aged 40–42 and 60–87 years, a 10% random sample of individuals aged 
30–39 years and a 40% random sample of individuals aged 43-59 were invited to 
participate (56). The first part of the survey consisted of a 4-page questionnaire 
covering various health issues that participants filled in at home before attending the 
study. A second questionnaire covered more details about the topics already covered 
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by the first questionnaire. The participants could either take it home to fill in or fill in 
at the study site while they were waiting for various physical examinations. The 
physical examinations included blood pressure, weight/height and hip/waist 
measurements, sampling of blood, hair and nose and throat swabs, measurements of 
pain sensitivity, single energy X-ray absorptiometry (SXA) measurement of forearm 
bone density and grip strength. The second part of the survey (about 4 weeks later) 
included dual-energy X-ray absorptiometry (DXA) measurement of BMD at the hip, 
vertebra and body composition. The study had an attendance rate of 66%, with 12984 
out of 19762 invitees attending (figure 5). The study population for this master thesis 
consists of all participants of Tromsø 6 (n=12981) and a subpopulation (n=3663) with 
bone mineral density measurements in the second part of the survey (figure 5).  





Information about osteoporosis and fracture was collected through self-reports 
obtained by questionnaires. All participants were considered as having osteoporosis 
and fracture if they answered, “yes” to the question “Have you ever had, or do you 
have osteoporosis?” and “yes” to any of the corresponding questions regarding 
fracture “Have you ever had a hip fracture?” “Have you ever had a wrist/forearm 
fracture?”. 
Participants with DXA measurements were classified into different categories of 
osteoporosis based on their T-score values from their BMD measured by DXA and 
their answer to the question regarding fracture (see table 2). T-score was calculated 
from BMD of the left hip by using the National Health and Nutrition Examination 
Survey (NHANES) III reference (57). The new values were categorized into 3 
categories based on the guidelines from The Norwegian Directorate of Health (T-
score < -2.5, -2.5 to -1.6 and > -1.6) (31).  
Information about drug use was collected through questionnaire that was filled in at 
home and was checked by trained health personnel at the study site. Anti-osteoporosis 
drug users were defined as those that answered, “yes” to the question “Do you use, or 
have you used drugs for osteoporosis?” and also those that listed the brand names of 
the drugs used.  
Based on the Anatomical Therapeutic Chemical (ATC) classification system (58), 
anti-osteoporosis drugs (AOD) were defined as bisphosphonates (ATC code 
M05BA), denosumab (M05BX04), PTH (H05AA02), SERM (G03XC01) and HRT 
(G03CA03, G03CA04, G03CX01, G03FA01, G03FA12 and G03FB05). Calcium 
supplements with vitamin D (A12A) were not defined as AOD but were included in 
tabulations because of its positive effect on bone and its recommendation in the 
prophylaxis and treatment of osteoporosis (31, 42).  
Participants from the subpopulation with BMD measurements that were in need of 




Table 2 Classification of T-score based on The Norwegian Directorate of Health guidelines 
(31)* 
T-score based on DXA 
measurements 
Fracture (hip or wrist) No fracture 
< -2.5 Established osteoporosis Osteoporosis 
-2.5 to -1.6  Clinical osteoporosis Osteopenia (in the lower 
range) 
> -1.6 Normal BMD Osteopenia in the upper 
range or normal BMD 
* Grey areas signifying groups who fulfill the criteria for anti-osteoporosis drug treatment 
 
The validation of the general question “Do you take medication for osteoporosis now” 
was done by using as the gold standard all self-reported listed brand names of anti-
osteoporosis drugs in the same questionnaire. 
The question on self-reported health had five response alternatives, but was 
dichotomized into good (excellent/ good /neither good nor bad) and bad (bad/very 
bad) for the statistical analyses.  
Bisphosphonate use was further studied among the participants who according to their 
T-score value and self-reported fracture should be recommended AOD treatment (see 
table 2). 
Signs of adverse reactions were defined based on the participant’s reports of 
symptoms such as muscle or joint pain, gastrointestinal symptoms such as heartburn, 
diarrhea, constipation, bloated stomach and abdominal pains during the last 12 
months. The use of drugs for acid related disorders and drugs for peptic ulcer and 
gastro-esophageal reflux disease were also included.  
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3.4 Data analysis 
Data analysis was performed with the statistical software program IBM SPSS 
statistics 23 for Mac. Differences between groups were analyzed using X2-test 
(categorical variables). Multiple logistic regression was conducted to assess 
associations while adjusting for potential confounding factors. The significance level 
was set at 5%. 
 
3.5 Ethics 
The Norwegian Data Protection Authority and the Regional Committee of Medical 
and Health Research Ethics, North Norway approved Tromsø 6. The study complies 
with the Declaration of Helsinki, International Ethical Guidelines for Biomedical 
Research Involving Human Subjects and the International Guidelines for Ethical 
Review of Epidemiological Studies. Participation was voluntary and each subject 




4.1 Characteristics of the study population 
Characteristics of the total population and the subpopulation are presented in table 3. 
The total population consisted of 6928 women and 6053 men with an overall average 
age of 57 years. The subpopulation, i.e. the participants with DXA measurements, 
consisted of 2151 women and 1512 men and had an overall average age of 65 years.  
The prevalence of AOD use reported through the general question and according to 
listed brand name seemed to be slightly higher in the subpopulation (5.2% and 5.5% 
respectively) compared with the total population (3.4% and 3.6% respectively).  
Wrist/forearm fracture was the most reported fracture type overall, and was higher 
among the subpopulation than among the total population (17.9% vs. 14.9%). 
Occurrence of hip fracture was higher in the total population than the subpopulation 
(1.8% vs. 1.4%). 
Men seem to have had a slightly higher BMI than women in both populations. Self-
reported health seemed to be similar in the two populations, with the majority of the 




Table 3 Characteristics of the study population 
  Total population 
N=12981 
Subpopulation 
N=3663   
    
Age, years (mean±SD) 57.5 (12.6) 65.8 (9.4) 
Age (n (%))    
30-39 years 509 (3.9) 12 (0.3) 
40-49 3574 (27.5) 135 (3.7) 
50-59 2436 (18.8) 715 (19.5) 
≥60 6462 (49.8) 2801 (76.5) 
    
Self-reported current AOD use (n (%)) 440 (3.4) 191 (5.2) 
30-39 years  1 (0.2) 0 (0.0) 
40-49 years  18 (0.5) 0 (0.0) 
50-59 years  36 (1.5) 12 (1.7) 
≥60 years  385 (6.2) 179 (6.7) 
    






40-49 years  18 (0.5) 1 (0.7) 
50-59 years  68 (2.8) 24 (3.4) 
≥60 years  379 (5.9) 177 (6.3) 
    
Fracture (%)    
Hip  240 (1.8) 50 (1.4) 
Wrist/forearm  1938 (14.9) 655 (17.9) 
    
BMI (mean±SD)    
Women  26.5 (4.6) 26.9 (4.6) 
Men  27.2 (3.7) 27.2 (3.4) 
    
Height, cm (mean±SD)    
Women  163 (6.5) 161 (6.3) 
Men  177 (6.8) 175 (6.5) 
    
Weight, kg (mean±SD)    
Women  70 (13.0) 70.6 (12.8) 
Men  85 (13.3) 83.7 (12.1) 
    
Self-reported health %    
Excellent  1873 (14.4) 380 (10.4) 
Good  6592 (50.8) 1835 (50.1) 
Neither good nor bad  3699 (28.5) 1235 (33.7) 
Bad  651 (5.0) 163 (4.4) 
Very bad  48 (0.4) 13 (0.4) 
AOD: Anti-osteoporosis drugs 
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4.2 Validation of the question regarding the use of drugs for anti-
osteoporosis drugs (AOD) 
When the general question was tested against the first gold standard (total AOD use 
according to brand name), The general question gave a sensitivity of 55% and a 
specificity of 98%. About 203 of 455 (45%) were “false negative” and 188 of 12667 
(1.5%) were “false positive” (Table 4). 
When tested against the second gold standard (bisphosphonates brand name), 
sensitivity was 99% and specificity was 98%. Three of 241 (1%) were “false 







Table 4 Validation of the general question regarding the use of drugs for osteoporosis 
   AOD brand name reported Bisphosphonates brand name 
   Yes No Total Yes No Total 
Self-reported 
current AOD use 
Yes 252 188 404 238 202 404 
No 203 12024 12227 3 12224 12227 
 Total 455 12212 12667 241 12426 12667 
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4.3 Prevalence of AOD use in the total population 
The prevalence of AOD use among the total population, types of AOD and calcium 
supplements with vitamin D used are presented separately for women and men in 
table 5.  
Participants are categorized into groups according to their reports of osteoporosis and 
fracture. Prevalence of AOD use overall was higher (50.9%) among participants 
reporting osteoporosis and fracture compared with participants reporting osteoporosis 
without fracture (41.2%). Both groups consisted of mostly women. The group 
reporting osteoporosis and fracture (n=175) consisted of 166 women and 14 men, the 
second group (n=262) reporting osteoporosis without fracture, consisted of 231 
women and 31 men. Bisphosphonates was the most frequently used anti-osteoporosis 
drug among both groups and across both gender. Prevalence of bisphosphonates use 
in the first group was 46.6% for women and 64.3% for the men. For the second group 
the prevalence was lower in both women (40.3%) and men (35.5%), and the 
difference most pronounced in men.  
PTH use was registered in only one male participant who reported osteoporosis and 
fracture. SERMs usage was registered among two females with osteoporosis but 
without fracture (not shown in table). 
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Table 5 Prevalence of self-reported anti-osteoporosis drug use among the total population (n = 12981) according to self-reported osteoporosis and fracture 
categorized by gender and anti-osteoporosis drug type 
 Total Women N=6928   Men N=6053  
Self-reported osteoporosis and 
fracture 
AOD use  Bisphosphonates HRT Calcium + 
vitamin D* 
 Bisphosphonates Calcium +  
vitamin D* 
 n (%) N n (%) n (%) n (%) N n (%) n (%) 
Osteoporosis +Fx  
N=175 
89(50.9) 161 75(46.6) 8(5.0) 39(24.2) 14 9(64.3) 5(35.7) 
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4.4 Prevalence of AOD use in the subpopulation 
Prevalence of AOD use among the different classifications of T-score for participants 
with DXA measurements, use of bisphosphonates, HRT and calcium supplements 
with vitamin D is presented in table 6. See table 2 for the classifications of T-score. 
Among 85 individuals with osteoporosis and fracture, prevalence of AOD use was 
17.6% (Table 6). The prevalence of AOD use was 15.6% for participants with 
osteoporosis without fracture and 10.2% for participants with clinical osteoporosis, 
i.e. T-score between -2.5 and -1.6 and with fracture. When AOD was divided into 
separate drug types, bisphosphonates were the most used drug type. Calcium 
supplements with vitamin D were also often used. Use of SERMs and PTH are not 
shown in Table 6. SERMs were registered only in one female participant with 




Table 6 Prevalence of self-reported AOD use among the subpopulation (n= 3663) according to T-score value and self-reported fracture categorized by gender 
and anti-osteoporosis drug type 
 Total Women 
N=2151 
   Men 
N=1512 
  
T-score with and without 
fracture 
AOD use  Bisphosphonates HRT Calcium + 
vitamin D* 
 Bisphosphonates Calcium + 
vitamin D* 
 N (%) N n (%) n (%) n (%) N n (%) n (%) 
< -2.5+Fx  
N=85 
15(17.6) 73 12(16.4) 0(0.0) 4(5.5) 12 2(16.7) 1(8.3) 
 

















































































































Total         
*Not included in total AOD use 
**Missing information on question regarding fracture 
+Fx: With fracture. -Fx: Without fracture
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4.5 Reports of osteoporosis within the subpopulation 
Figure 5 shows the classifications of T-score and reports of fracture within the 
subpopulation and the percentage of participants that reported having osteoporosis in 
each group. A total of 3546 (96.8%) of the 3663 participants in the subpopulation had 
answered the question regarding having osteoporosis. Reports of osteoporosis were 
low among the three groups that are recommended treatment with AOD. Among 
those with osteoporosis with or without fracture, only 32.9% and 19.2%, respectively, 
of the participants reported that they had osteoporosis. In the group defined as clinical 
osteoporosis, 14.8% of the participants reported that they had osteoporosis. In the 
groups with normal bone mass, the reports of osteoporosis were 7.7% for participants 
with fracture and 2.2% for those without fracture. Overall, reports of osteoporosis 




Figure 6 The proportion of participants reporting osteoporosis among the different T-score categories with or without fracture N= 3546. Participants who had 
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4.6 Factors associated with bisphosphonates use 
Based on their T-score and reports on fracture, 409 participants were identified as 
persons eligible for anti-osteoporosis drug treatment, i.e. bisphosphonates. In this sub 
group the association between factors like self-reported health, factors indicating 
gastrointestinal symptoms and muscle and joint pain and bisphosphonate use were 
analyzed in a binary logistic regression (Table 7). 
The regression analysis confirmed the significance of health as a factor associated 
with bisphosphonate use. Participants that perceived their health as poor had a higher 
odds of being users of bisphosphonates (OR 3.10, 95% CI 1.23-8.57). There was no 
statistically significant association between factors indicating gastrointestinal 
symptoms or muscle and joint pain. 
 
 27 
Table 7 Factors influencing prevalent use of bisphosphonates among participants eligible for anti-osteoporosis drug treatment. 
 Use of bisphosphonates 
YES 
(N=45) 
Use of bisphosphonates  
NO 
(N=364) 
Unadjusted  Adjusted*  
 n (%)  n (%)  OR 95% CL OR 95% CL 
Self-reported health       
Good 38(86.4) 346(95.3) 1 Reference 1  
Poor 6(13.6) 17(4.7) 3.21 1.20-8.64 3.10 1.23-8.57 
Factors indicating 
gastrointestinal symptoms** 
      
No 10(22.2) 62(17.6) 1 Reference 1  
Yes 35(77.8) 290(82.4) 0.75 0.35-1.59 0.60 0.27-1.32 
Muscle and joint pain**       
No 5(11.1) 71(20.2) 1 Reference 1  
Yes 40(88.9) 281(79.8) 2.02 0.77-5.31 1.88 0.69-5.11 
*The association between use of bisphosphonates and self-reported health, factors indicating gastrointestinal symptoms and muscle and joint pain were each 




Previous history of hip and forearm fracture is associated with low bone mineral 
density and subsequent fractures (59). Norway has one of the highest rates of hip and 
forearm fracture in the world (7), and one would expect a high prevalence of anti-
osteoporosis drug use among persons that are recommended treatment with AOD. 
Findings in this study show that this is not the case. 
We found that the use of anti-osteoporosis drugs among persons eligible for anti-
osteoporosis drug treatment was low. The prevalence was less than 50% among 
women and men reporting that they had osteoporosis in the total population. The 
prevalence was slightly higher among participants reporting osteoporosis and fracture. 
The prevalence of anti-osteoporosis drug use was less than 18% among participants 
with osteoporosis, as measured by DXA, in the subpopulation. We also found out that 
among the participants classified as having osteoporosis based on their T-score value, 
only 20% were aware of their condition. There are several possible reasons for this 
low usage of anti-osteoporosis drugs found in this study, and one very important 
factor is adherence to long-term drug therapy.  
Low adherence to oral drug therapy in chronic conditions is considered a public 
health problem (60). Adherence to therapy has become one of the major challenges in 
the treatment of osteoporosis (61). It is estimated that only half of the patients comply 
with long-term therapy. Approximately 50% of the women receiving anti-
osteoporosis drug treatment for the first time discontinue their treatment within one 
year (62). In Norway, only 45.5% of osteoporosis patients were adherent of 
alendronate treatment within five years of treatment (63). Studies show that poor 
adherence to bisphosphonate therapy is associated with increase in the risk of fracture 
and smaller gains in bone mineral density (62). Gastrointestinal adverse effects from 
bisphosphonates given orally as well as the complex intake regime, which requires 
patients to remain upright and be fasting when administrating the drug, are probably 
the main reason for patients to discontinue treatment (64, 65). Long-term adherence to 
anti-osteoporosis drug therapy is needed for optimal therapeutic benefits (33). Patients 
might also stop treatment because of the benefit not being immediate and they might 
fail to see the importance of taking the drug. 
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In this study, the association between gastrointestinal adverse effects and 
bisphosphonate use was not statistically significant. We found a higher prevalence of 
gastrointestinal adverse effects among non-users of bisphosphonates. This is 
surprising because normally, reports of adverse effects are more frequent among users 
of a drug. However, this can also be interpreted, as non-users having gastrointestinal 
adverse effects might be the reason why they are not using bisphosphonates.  
Some bisphosphonates formulations, especially alendronate and zolendronate have a 
prolonged dosing interval. Alendronate administrated orally once weekly have been 
shown to improve patients’ adherence (63), but could also potentially have lead 
participants to forget to report the use of the drug when the survey was conducted. It 
has been shown that patients recall more often drug that need more refill and drugs 
that are administrated frequently (66). Participants receiving zolendronate (Aclasta®) 
injections once a year could forget that they use any anti-osteoporosis drugs if it had 
been some months in between the time of the dose and the time they answered the 
survey. But with alendronate consisting of 93% of all bisphosphonates reported, we 
do not think this is a major problem with our study.   
Another explanation for the low prevalence in this study could be misclassification. 
Some participants could have reported having osteoporosis even though they might 
not have the disease. Reasons for this could be if the person have sustained a previous 
fracture, there is a family history of fracture and osteoporosis or they may think they 
have the disease based on their old age. Thus leading to an artificially low reporting 
of anti-osteoporosis drug use among participants reporting osteoporosis. 
The rules of reimbursement for alendronate in Norway up until 2012 was that one 
must have suffered a fracture and also had a bone mineral density measurement with a 
T-score ≤ -2.5 before a patient could receive full reimbursement. This could explain 
the low prevalence in anti-osteoporosis drug use, since Tromsø 6 was carried out 
during 2007-2008. In 2012 the reimbursement regulations were changed, excluding 
the requirement of having fracture before patients could get fully reimbursed (67). If 
lack of reimbursement has influenced our data from Tromsø 6, we might expect a 
higher prevalence in anti-osteoporosis drug use in Norway after 2012. 
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Osteoporosis is known as a silent disease as it does not give any symptoms and it is 
often not diagnosed until the occurrence of fracture. With this in mind, it is not 
surprising that a considerable proportion of participants were not aware of their 
condition, although they had DXA measurements that classified them as having 
osteoporosis. The University Hospital of North Norway is the only place where the 
DXA station is located in the municipality of Tromsø. Studies have shown that due to 
the unavailability of diagnostic tools in primary health care, over 75% of osteoporosis 
patients are not diagnosed and given treatment (68). Distance to DXA facilities has 
also been shown to influence the persons’ attendance to DXA examinations (69). 
Diagnosis and initiation of treatment could therefore increase with the availability of 
diagnostics in primary health care, which could also lead to an increased focus on 
osteoporosis. Reports of osteoporosis was however, high among participants with 
previous fracture. This could be because of the increase in awareness and concern 
about their health status after experiencing such a serious outcome as a fracture. A 
Norwegian study reported that there is a correlation between risk factors such as 
previous fracture and persons’ attendance to DXA examinations (69). 
In our study self-reported health was significantly associated with using 
bisphosphonate, with the odds of being a user of bisphosphonates three times higher 
among those with poor health compared to those with good health. However, we 
cannot conclude that users of bisphosphonates had poor health because of 
bisphosphonate usage and vise versa. One explanation for this finding could be that 
individuals with poor health maybe more health conscious and are more likely to visit 
the doctor’s office which increases their chances of being prescribed drugs.  
Several studies have reported similar low prevalence in anti-osteoporosis drug use. In 
line with our findings, one study based on a population in central Norway and 
including data linkage between the fracture registry in Nord-Trøndelag county and the 
Norwegian Prescription Database (NorPD) examined the use of anti-osteoporosis 
drugs the first year after fracture in central Norway. The study included 1434 women 
and 513 men 40-84 years with their first forearm fracture between 2005 and 2012. 
The prevalence of anti-osteoporosis drugs use after the first year of fracture was 
11.2% for women and 2.7% for men (52). Another study involving all Norwegian 
women and men ≥50 years based on data from the Norwegian Prescription Database, 
the National Hip Fracture Database, the National Population Register and the 
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Nationwide Census reported that 16% of women and 4 % of men were treated with 
anti-osteoporosis drugs within 2 years after a hip fracture (25). In a nationwide survey 
involving 51,346 patients over age 65 admitted to 318 hospitals in the US for hip 
fracture, only 7.3% were prescribed anti-osteoporosis drugs (70). In a study from 
Belgium, just 6% of patients who had sustained a hip fracture received treatment with 
anti-osteoporosis drugs (53). All these studies show that undertreatment of 
osteoporosis is not only a problem in Norway, but also worldwide. 
5.1 Validity 
The general question “Do you take medication for osteoporosis now?” had a 
sensitivity of 55% and a specificity of 98% when the question regarding use of anti-
osteoporosis drugs according to listed brand names was used as a gold standard. This 
means that the general question regarding use of drugs for osteoporosis have a very 
good chance of detecting those that actually do not use any anti-osteoporosis drugs 
(true negatives), but not as good when it comes to detecting those that actually do use 
anti-osteoporosis drugs (true positives). However, when self-reported use of 
bisphosphonates was used as the gold standard sensitivity was 99% and specificity 
98%. This means that the question regarding use of drugs for osteoporosis have a very 
good chance of detecting persons that use bisphosphonates (true positives), and it is 
also just as good to detect persons that are not bisphosphonate users. This high 
sensitivity probably has to do with how the participants define drugs used for 
osteoporosis. The first gold standard, which includes all anti-osteoporosis drugs used, 
is not as specific as the second gold standard because it includes all anti-osteoporosis 
drug types, including SERMs, PTH and HRT. Among the 203 false negatives, 200 
participants were found to be users of HRT and three were bisphosphonate users. 
Unlike bisphosphonates, HRT is indicated for more than just the treatment of 
osteoporosis. Participants using HRT for the treatment of menopausal symptoms such 
as hot flashes may therefore fall in the false negative group since HRT was defined as 
an AOD in this study. This might also be the case for participants that are receiving 
glucocorticoid therapy and also using bisphosphonates as a prophylaxis for 
osteoporosis. 
In the cross-tabulation for self-reported current use of anti-osteoporosis drug against 
the self-reported use of anti-osteoporosis drug according listed brand names, 68 
participants among the false positive group were found to be users of calcium 
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supplement with vitamin D. The calcium supplements with vitamin D in this study are 
prescription based and it is recommended in the prophylaxis of osteoporosis. This 
might have confused patients into thinking that it is medical treatment whilst in 
clinical practice it is considered a supplement. 
Overall the general question in the questionnaire regarding the current use of drugs 
for osteoporosis is very good in identifying participants using bisphosphonates. 
5.2 Strengths and limitations  
The strength of this study is the use of data from the Tromsø study, a large 
population-based study with a high attendance rate. Tromsø 6 has an attendance rate 
of 66%, which is somewhat lower compared to previous waves of the Tromsø study, 
but it is still considered very good compared to other similar population surveys. 
Tromsø 6 has good external validity. The majority of the attendees were ≥50 years 
and with osteoporosis being a disease that normally affects people ≥50 years, we can 
conclude that the findings in this study is therefore generalizable to the source 
population.  
The availability to DXA measurement of the participants is also a major strength of 
this study. Diagnostic data interpreted by trained health personnel, makes it possible 
to correctly classify participants in the different categories of T-score.  
Data involved in Tromsø 6 was collected by questionnaire. The advantage with this 
data collecting method is the ability to easily collect information about a large number 
of different variables from a large study population. However, the use of 
questionnaire has it challenges. Researchers must rely on participants remembering 
and reporting the right information. Studies show that self reports on fracture is very 
accurate in detecting major fractures such as hip and wrist fractures (71). But it is 
however often over reported (72). This could lead to a misclassification of 
participants and an under estimation of the prevalence of anti-osteoporosis drug use.   
Several studies have examined self-reported recall accuracy for current or past drug 
use (66). The majority of people generally remember quite accurately when they have 
used prescription-based drugs, although they might not remember actual brand names. 
This may lead to an underreporting of anti-osteoporosis drug used by participants in 
this study. However, the questionnaire in Tromsø 6 was answered by participants at 
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the comforts of their homes where they had access to the drugs they take, making it 
easy to remember and list the brand names of the anti-osteoporosis drugs that they are 
using. 
One requirement for the Tromsø study was the ability of participants to fill in a 
questionnaire and to visit the study site. This requirement may lead to a selection bias 
into the population because the oldest people that are weak and frail with potential 
cognitive issues may fail to attend the study. Information is lost for researchers not 
being able to include these old persons (56).  
In this study the question on self-reported health was dichotomized into good 
(excellent/ good /neither good nor bad) and bad (bad/very bad) for the statistical 
analyses. The reason for this is the low number of participants in the different 
categories (table 3). Participants reporting neither good nor bad health were 
categorized as good because it was assumed that an individual reporting neither good 
nor bad health has good health but might think it is not as good. A person with bad 
health might be less likely to report having neither good nor bad health. 
This master thesis is an observational cross-sectional study, a design which is suitable 
for describing the prevalence of risk factors and outcomes in a population. But it 
cannot measure disease incidence because of its lack of a time dimension, which 






The prevalence of anti-osteoporosis drug use among persons eligible for treatment is 
very low, although higher among persons reporting osteoporosis and fracture. With 
the availability of cost effective therapies and with clinical consequences such as 
fracture-associated morbidity and mortality, as well as the economical burden on 
society, we can conclude that prevalence of anti-osteoporosis drug use is too low and 
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